The susceptibility of Pseudomonas aeruginosa strains from cystic fibrosis patients to bacteriophages.
about
Bacteriophage-based therapy in cystic fibrosis-associated Pseudomonas aeruginosa infections: rationale and current statusPhage Therapy: a Step Forward in the Treatment of Pseudomonas aeruginosa InfectionsA novel Pseudomonas aeruginosa bacteriophage, Ab31, a chimera formed from temperate phage PAJU2 and P. putida lytic phage AF: characteristics and mechanism of bacterial resistance.Abundant and diverse clustered regularly interspaced short palindromic repeat spacers in Clostridium difficile strains and prophages target multiple phage types within this pathogenBacteriophage resistance mechanisms in the fish pathogen Flavobacterium psychrophilum: linking genomic mutations to changes in bacterial virulence factorsPseudomonas aeruginosa adaptation to lungs of cystic fibrosis patients leads to lowered resistance to phage and protist enemiesThe search for therapeutic bacteriophages uncovers one new subfamily and two new genera of Pseudomonas-infecting Myoviridae.Characterization of the Newly Isolated Lytic Bacteriophages KTN6 and KT28 and Their Efficacy against Pseudomonas aeruginosa Biofilm.Investigation of a Large Collection of Pseudomonas aeruginosa Bacteriophages Collected from a Single Environmental Source in Abidjan, Côte d'Ivoire.In vitro and in vivo antibacterial activity of environmental bacteriophages against Pseudomonas aeruginosa strains from cystic fibrosis patients.Phylogenetic Distribution of CRISPR-Cas Systems in Antibiotic-Resistant Pseudomonas aeruginosa.Genetic Evidence for O-Specific Antigen as Receptor of Pseudomonas aeruginosa Phage K8 and Its Genomic Analysis.Large Preferred Region for Packaging of Bacterial DNA by phiC725A, a Novel Pseudomonas aeruginosa F116-Like BacteriophageCharacterization and Comparative Genomic Analyses of Pseudomonas aeruginosa Phage PaoP5: New Members Assigned to PAK_P1-like VirusesIdentification of bacteriophages for biocontrol of the kiwifruit canker phytopathogen Pseudomonas syringae pv. actinidiae.Liposomal antibiotic formulations for targeting the lungs in the treatment of Pseudomonas aeruginosa.New perspectives in the management of Pseudomonas aeruginosa infections.Pseudomonas aeruginosa: arsenal of resistance mechanisms, decades of changing resistance profiles, and future antimicrobial therapies.Effects of storage conditions on the stability of spray dried, inhalable bacteriophage powders.Bacterial competition and quorum-sensing signalling shape the eco-evolutionary outcomes of model in vitro phage therapyPre-adapting parasitic phages to a pathogen leads to increased pathogen clearance and lowered resistance evolution with Pseudomonas aeruginosa cystic fibrosis bacterial isolates.Production of Inhalation Phage Powders Using Spray Freeze Drying and Spray Drying Techniques for Treatment of Respiratory Infections.Challenges and Promises for Planning Future Clinical Research Into Bacteriophage Therapy Against Pseudomonas aeruginosa in Cystic Fibrosis. An Argumentative Review.Transposition Behavior Revealed by High-Resolution Description of Pseudomonas Aeruginosa Saltovirus Integration Sites.
P2860
Q26799417-97AAC04B-7577-4E5C-AAC6-3AECB0A530BBQ26823401-403CE884-C6BC-46E7-9D20-BD5A53E9403DQ31156429-AD13C0C5-8157-4AAD-B616-E25148EC4820Q34237789-12B9CB8C-106A-4AE3-83B4-99AA6E9F18DDQ34933698-DD28DC60-55F4-4495-A563-1BAA4ECE1DE0Q34999578-77252186-E1F3-44DD-A45B-30908DAB55A8Q35023371-79073C45-A580-4FC7-90E3-2F3D47A9802BQ35634231-B258D895-F806-4F67-9920-782A61A8FDE6Q35675668-F64C6668-340C-4495-9E0D-3E17A5F54E07Q35780029-B1B5279C-BEDC-4230-A693-6DF81A75739FQ35851888-EFD3EB0F-124E-4193-920C-058845544CABQ35955662-B717082D-2A55-4612-A2D6-5335A738DD8AQ36242867-33B27722-AABF-429B-BC20-B6BF1D209BE9Q37278146-B0D1BBF6-DD34-49B8-9FB4-382E0F3AF60BQ37712894-50F2ACB0-C71E-41FF-AF3C-9B1A5D0EC599Q38214155-9647C38B-2BD0-407B-9C01-D7621E409E12Q38243221-D7096785-1658-4E34-8BC5-B1637C6E12CAQ38599969-2A8AC2F0-1B4D-4939-99A4-B18F6FB2FB36Q40344566-39BCDAA1-AB41-451B-8E2D-C782C1E87353Q40356497-A56AAD8F-2AB0-4B14-B018-B311532BC929Q40421266-9B0ABBED-697A-4C4A-A4CC-C880EC19261FQ40772570-EE9606EE-224A-4E0F-93ED-3C0DA0923701Q54205022-B2861641-D11D-468D-9872-0CD79A3C7EDCQ54936187-DFD519D5-726E-4DBB-9B80-07BBCCC96179
P2860
The susceptibility of Pseudomonas aeruginosa strains from cystic fibrosis patients to bacteriophages.
description
2013 nî lūn-bûn
@nan
2013 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
The susceptibility of Pseudomo ...... is patients to bacteriophages.
@ast
The susceptibility of Pseudomo ...... is patients to bacteriophages.
@en
The susceptibility of Pseudomo ...... is patients to bacteriophages.
@nl
type
label
The susceptibility of Pseudomo ...... is patients to bacteriophages.
@ast
The susceptibility of Pseudomo ...... is patients to bacteriophages.
@en
The susceptibility of Pseudomo ...... is patients to bacteriophages.
@nl
prefLabel
The susceptibility of Pseudomo ...... is patients to bacteriophages.
@ast
The susceptibility of Pseudomo ...... is patients to bacteriophages.
@en
The susceptibility of Pseudomo ...... is patients to bacteriophages.
@nl
P2093
P2860
P921
P1433
P1476
The susceptibility of Pseudomo ...... sis patients to bacteriophages
@en
P2093
Arsher Cablanmian
Christiane Essoh
Elizabeth Kutter
Guillaume Loukou
Hoang Vu Thien
Serge Lathro
Yann Blouin
P2860
P304
P356
10.1371/JOURNAL.PONE.0060575
P407
P577
2013-04-24T00:00:00Z